Read on Twitter
This week marks 
years of biosimilar medicines in Europe. They have greately contributed to better access across Europe and beyond. Thread 
#biosimilars #access4all https://twitter.com/medicinesforEU/status/1381555506960027651
years of biosimilar medicines in Europe. They have greately contributed to better access across Europe and beyond. Thread #biosimilars #access4all https://twitter.com/medicinesforEU/status/1381555506960027651
In 
Germany , today patients with rheumatoid arthritis get access to biologics in 0.3 years in comparison to 7.4 years before #biosimilars were introduced. @ProBiosimilars @medicinesforEU
Germany , today patients with rheumatoid arthritis get access to biologics in 0.3 years in comparison to 7.4 years before #biosimilars were introduced. @ProBiosimilars @medicinesforEU
A milestone has been the introduction of #biosimilar adalimumab. In 
Denmark, with introduction of ada biosimilars, they have managed a national switch in just 3 weeks for 90% of use! Saved DKK 350 million in 2019 alone. https://bit.ly/3daEuFw
Denmark, with introduction of ada biosimilars, they have managed a national switch in just 3 weeks for 90% of use! Saved DKK 350 million in 2019 alone. https://bit.ly/3daEuFw
UK: In the first year of adalimumab #biosimilar competition entering the market, NHS optimised spent on adalimumab alone by £110million, allowing NHS to reinvest the money in other treatments. https://bit.ly/3g5FlJv @BritBiosimilars
Several biologics that have biosimilar versions are being added to @WHO essential medicines list and prequalified. These are esential treatments such as insulins https://bit.ly/3wRd5jS Very important for greater access globally.
There is much more to be done - lack of uptake in CEE region - also where we can observe issues with access to biologic treatments. Comprehensive uptake policies could make a big difference. Check out @medicinesforEU marker review 2020 https://bit.ly/3uJFA10
If you are interested to learn more about early days read @Julie_MarJam blog with perspectives of different stakeholders, The beginning of biosimilar medicines journey https://bit.ly/3mHYEK9
And finally, future perspective: By 2025, over 70% of new meds registered will be biologics. This is why it will be important to optimise the current framework and support introduction to markets as indicated in plans by @EMA_News and @EU_Health to achieve #access4all
